FGF2 and metastatic prostate carcinoma: Although the vast majority (18/19, 94.7%) of patients with metastatic prostate cancer tested positively for CTCs when examined with the CellCollector® and/or dual fluoro-EPISPOTPSA/FGF2 assay and/or CellSearch® system, an equally large proportion of the positive results was documented in the non-metastatic group (Table 4).